Table 1. Characteristics of included studies. References Patients’ Status/Treatment Stage Sample Size Age (yrs)/Country CART Intervention (training parameters) Length (wks) Setting/Cancer Stage BMI ± SD (kg/m2) Outcome Measures (Dieli-Conwright et al., 2018) BC survivors After treatment N: 91 EX: 46 C: 45 EX: 52.8 ± 10.6 CO: 53.6 ± 10.1 United States AE: 2–3 d/wk, 150 min, 40%–50% HRR; RT: 3 d/wk, 40%–50% 1-RM 16 Supervised/Stage: I, II, III EX: 33.1 ± 5.7 C: 33.4 ± 5.2 HDL-C, TC, TG, CRP, TNF-α, IL-6, LEP, BM, BF, FM, FFM, WC, HC, QoL, FA (Dieli-Conwright et al., 2018) Cont. BC survivors After treatment N: 20 EX: 10 C: 10 EX: 53.0 ± 10.0 CO: 55.0 ± 4.5 United States Supervised/Stage: I, III EX: 33.5 ± 5.7 C: 33.3 ± 8.7 BF, ADPN, IL-8, LDL (Dieli-Conwright et al., 2018) Cont. BC survivors After treatment N: 100 EX: 50 C: 50 Total: 52 ± 10.4 United States AE: 2 d/wk, 80 min, 65%–80% HRmax; RT: 2–3 d/wk, 60% 1-RM 16 Supervised/Stage: 0, III Total BMI: 33.5 ± 5.5 SQ (Dieli-Conwright et al., 2019) BC survivors After treatment N: 56 EX: 29 C: 27 EX: 46.9 ± 10.2 C: 46.7 ± 10.0 United States AE: 2–3 d/wk, 150 min, 40% –50% HRR; RT: 2–3 d/wk, 80% 1-RM 16 Supervised/Stage: I, II, III EX: 35.1 ± 6.1 C: 34.7 ± 6.4 BM, WC, HC, BF, FM, FFM, SBP, DBP, FG, FI, TC, HDL-C, LDL-C, TG, CRP, QoL (Dieli-Conwright et al., 2022) BC survivors After treatment N: 25 EX: 13 C: 12 EX: 59.5 ± 6.5 C: 54.1 ± 10.6 United States AE+RT, 150 m/wk plus home-based AE 970 min/wk) 24 Supervised & home-based/Stage: I, III EX: 29.5 ± 3.6 C: 36.4 ± 6.1 BMI, LEP (Brown et al., 2021) BC survivors After treatment N: 177 EX: 87 C: 90 EX: 59.1 ± 8.1 C: 59.0 ± 8.5 United States AE: 3–6 d/wk, 180 min/wk, 50%–70% HRmax; RT: 2 d/wk, 2–3 sets x 10 reps. 52 Supervised & home-based/Stage: I, III EX: 34.0 ± 6.2 C: 34.0 ± 5.7 BM, FM, BMD (Ergun et al., 2013) BC survivors After treatment N: 40 EX: 20 C: 20 EX: 49.7 ± 8.35 C: 50.3 ± 10.4 Turkey AE + RT: for 45 min/D for 3d/wk and brisk walking for 30 min/D for 3 d/wk 12 Supervised/Stage: N/A EX: 26.6 ± 4.4 C: 28.6 ± 5.2 FA, IL-6, IL-8, TNF-α, QoL, DEP (Rogers et al., 2013) BC survivors After treatment N: 28 EX: 15 C: 13 EX: 58.0 ± 6.1 C: 53.7 ± 13.9 United States AE: 150 min/wk; RT: 2 d/wk, 60%–70% 1-RM 12 Supervised & home-based/Stage: I, II, III EX: 33.9 ± 7.4 C: 30.3 ±7.11 BMI, BF, FM, WHR, FA, IL-1β, IL-6, IL-8, IL-10, TNF-α, LEP (Rogers et al., 2014) BC survivors After treatment N: 42 EX: 20 C: 22 EX: 57.2 ± 5.5 C: 55.2 ± 9.1 United States AE: 160 min/wk; RT: 2 d/wk, 60%–70% 1-RM 12 Supervised & home-based/Stage: I, III EX: 29.8 ± 4.8 C: 32.6 ± 6.6 FA, BMI, BF, IL-6, IL-8, IL-10, TNF-α, SQ (Hutnick et al., 2005) BC survivors After treatment N: 36 EX: 21 C: 15 EX: 48.5 ± 10.6 C: 52.3 ± 9.2 United States AE+RT (40–90 min), 3 d/wk, 60%–75% HRmax/1-RM 24 Supervised & home-based/Stage: I, II, III EX: 26.7 ± 5.45 C: 26.7 ± 4.5 BM, BMI, BF, CRF, IL-6 (Battaglini et al., 2007) BC patients During treatment N: 20 EX:10 C: 10 EX 57.5 ± 23.0 C: 56.6 ± 16.0 United States AE+RT (60 min), 2 d/wk, 40%–60% HRR/1-RM 21 Supervised/Stage: N/A EX: 77.5 ± 27.3 C: 82.2 ± 25.0 FFM, Muscular Strength (Mutrie et al., 2007) BC patients. During treatment N: 181 EX: 82 C: 95 EX: 51.3 ± 10.3 C: 51.8 ± 8.7 United Kingdom AE+RT (45 min), 2 d/wk, 50%–75% HRR/1-RM 12 Supervised & home-based/Stage: 0, III EX: 27.3 ± 5.2 C: 27.5 ± 6.0 BMI, QoL, FA, DEP, Physical Function (Nieman et al., 1995) BC survivors After treatment N: 12 EX: 6 C: 6 EX: 60.8 ± 4.0 C: 51.2 ± 4.7 United States AE+RT, (60 min), 3 d/wk, 75% HRR/1-RM 8 Supervised / Stage: N/A EX: 67.6 ± 3.7 C: 75.5 ± 9.8 CRF (Ligibel et al., 2008) BC survivors After treatment N: 82 EX: 40 C: 42 EX: 52.0 ± 9.0 C: 53.0 ± 9.0 United States AE: 90 min/wk, 2 d/wk; RT: 50 min/wk, 2 d/wk 16 Supervised & home-based/Stage: I, II, III EX: 30.3 ± 5.9 C: 31.4 ± 6.8 BM, BMI, WC, HC, WHR, BF, LEP, ADPN (Ligibel et al., 2019) BC patients Before treatment N: 48 EX: 26 C: 22 EX: 52.3 ± 9.6 C: 53.1 ± 7.9 United States AE: 180 min/wk; 60%–70% HRmax; RT: 40 min/wk, 60%–70% 1-RM 16 Supervised & home-based/Stage: I, II, III EX: 30.7 ± 6.1 C: 29.1 ± 7.4 LEP, CRP, IL-6 (Jones et al., 2020) BC survivors After treatment N: 51 EX: 26 C: 25 EX: 55.8 ± 7.2 C: 55.9 ± 7.1 New Zealand AE+RT (60 min), 2 d/wk 12 Supervised/Stage: I, II, III EX: 27.8 ± 5.5 C: 27.5 ± 4.8 BM, BMI, FM, BF, SBP, DBP, CRF (Lee et al., 2019) BC survivors After treatment N: 91 EX: 46 C: 45 Total: 53.5 ±10.4 United States AE: ≥150 min, 2–3 d/wk, 65%–80% HRmax; RT: 2–3 d/wk 16 Supervised/Stage: I, III BM1 ≥25.0 or BF ≥30% TC, LDL-C, HDL-C, TG (Saxton et al., 2014) BC survivors After treatment N:85 EX: 44 C: 41 EX: 55.8 ± 10.0 C: 55.3 ± 8.8 United Kingdom AE: 30 min, 65%–85% HRmax, 3 d/wk; RT: 10–15 min, 2–3 d/wk 24 Supervised/Stage I, III EX: 29.7±3.5 C: 31.1 ± 5.7 IL-6, TNF-α, NK cell (Scott et al., 2013) BC survivors After treatment N: 83 EX: 43 C: 40 EX: 55.6 ± 10.2 C: 55.9 ± 8.9 United Kingdom AE: 30 min, 65%–85% HRmax, 3 d/wk; RT: 10–15 min, 2–3 d/wk 24 Supervised/Stage: I, III EX: 29.6 ± 3.5 C: 31.1 ± 5.6 CRF, SBP, DBP, FG, CRP, TC, HDL-C, LDL-C, QoL, LEP ADPN: Adiponectin, AE: Aerobic Exercise, BC: Breast Cancer, BF: Body Fat, BM: Body Mass, BMI: Body Mass Index, BMD: Bone Mineral Density, C: Control Group, CART: Combined Aerobic and Resistance Training, CRF: Cardiorespiratory Fitness, CRP: C-Reactive Protein, DBP: Diastolic Blood Pressure, DEP: Depression, EX: Exercise Group, FA: Cancer-related Fatigue, FFM: Fat-Free Mass, FG: Fasting Glucose, FI: Fasting Insulin, FM: Fat Mass, HC: hip circumference, HDL-C: High-Density Lipoprotein Cholesterol, HRmax: Maximum Heart Rate, HRR: Heart Rate Reserve, IL: Interleukin, LEP: Leptin, LDL: Low-Density Lipoprotein Cholesterol, NK: Natural Killer, RT: Resistance Training, SBP: Systolic Blood Pressure, SQ: Sleep Quality, TC: Total Cholesterol, TG: Triglycerides, TNF-α: Tumor Necrosis Factor α, QoL: Quality of Life, WC: Waist circumference, WHR: Waist-to-Hip Ratio, 1-RM: Repetition Maximum.